Free Trial
Your Portfolio Deserves Better! MarketBeat All Access for Just $149
Upgrade Now
Claim MarketBeat All Access Sale Promotion

Sana Biotechnology (SANA) Financials

Sana Biotechnology logo
$2.92 -0.12 (-3.91%)
As of 09:35 AM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for Sana Biotechnology

Annual Income Statements for Sana Biotechnology

This table shows Sana Biotechnology's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -131 -285 -356 -269 -283 -267 -244
Consolidated Net Income / (Loss)		 -131 -285 -356 -269 -283 -267 -244
Net Income / (Loss) Continuing Operations		 -131 -285 -356 -269 -283 -267 -244
Total Pre-Tax Income 		-138 -285 -356 -269 -283 -267 -246
Total Operating Income		 -141 -286 -357 -273 -293 -273 -250
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 141 286 357 273 293 273 250
Selling, General & Admin Expense		 22 28 50 72 73 64 44
Research & Development Expense		 119 258 306 201 213 207 161
Impairment Charge		 - - - - 7.01 1.89 45
Total Other Income / (Expense), net		 2.83 0.84 0.98 3.09 9.89 5.96 3.85
Interest & Investment Income		 2.86 0.75 0.68 3.76 9.94 10 3.85
Other Gains / (Losses), net		 - - - - - - 2.31
Basic Earnings per Share		 ($26.68) ($21.92) ($2.14) ($1.43) ($1.46) ($1.16) ($0.96)
Weighted Average Basic Shares Outstanding		 4.90M 13.01M 166.43M 188.34M 194.54M 230.89M 253.23M
Diluted Earnings per Share		 ($26.68) ($21.92) ($2.14) ($1.43) ($1.46) ($1.16) ($0.96)
Weighted Average Diluted Shares Outstanding		 4.90M 13.01M 166.43M 188.34M 194.54M 230.89M 253.23M
Weighted Average Basic & Diluted Shares Outstanding		 4.90M 13.01M 166.43M 191.36M 220.45M 225.02M 266.87M

Quarterly Income Statements for Sana Biotechnology

This table shows Sana Biotechnology's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 0.98 -88 -107 -50 -60 -49 -49 -94 -42 -59 -47
Consolidated Net Income / (Loss)		 0.98 -88 -107 -50 -60 -49 -49 -94 -42 -59 -47
Net Income / (Loss) Continuing Operations		 0.98 -88 -107 -50 -60 -49 -49 -94 -42 -59 -47
Total Pre-Tax Income 		0.98 -88 -108 -50 -60 -49 -49 -94 -42 -61 -47
Total Operating Income		 -2.18 -91 -111 -49 -62 -51 -51 -95 -44 -61 -49
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 2.18 91 111 49 62 51 51 95 44 61 49
Selling, General & Admin Expense		 19 21 16 16 14 17 11 10 10 12 11
Research & Development Expense		 -17 70 94 33 48 34 39 40 33 49 37
Impairment Charge		 - - - 0.00 0.00 - 0.00 45 0.00 - 0.00
Total Other Income / (Expense), net		 3.17 2.46 3.03 -0.92 1.84 1.80 1.24 1.18 1.36 0.07 1.40
Interest & Investment Income		 2.86 2.73 3.03 3.20 2.58 1.66 0.99 0.58 1.00 1.28 0.95
Other Income / (Expense), net		 0.30 - - -4.12 -0.74 0.14 0.25 0.60 0.36 - 0.45
Basic Earnings per Share		 $0.00 ($0.44) ($0.49) ($0.21) ($0.25) ($0.21) ($0.21) ($0.39) ($0.16) ($0.20) ($0.17)
Weighted Average Basic Shares Outstanding		 196.98M 194.54M 217.29M 234.44M 235.41M 230.89M 237.58M 238.41M 260.49M 253.23M 276.86M
Diluted Earnings per Share		 $0.00 ($0.44) ($0.49) ($0.21) ($0.25) ($0.21) ($0.21) ($0.39) ($0.16) ($0.20) ($0.17)
Weighted Average Diluted Shares Outstanding		 200.47M 194.54M 217.29M 234.44M 235.41M 230.89M 237.58M 238.41M 260.49M 253.23M 276.86M
Weighted Average Basic & Diluted Shares Outstanding		 197.13M 220.45M 221.50M 222.47M 223.27M 225.02M 225.56M 237.81M 266.37M 266.87M 278.29M

Annual Cash Flow Statements for Sana Biotechnology

This table details how cash moves in and out of Sana Biotechnology's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 50 45 135 -75 -50 -5.95 -55
Net Cash From Operating Activities		 -86 -138 -251 -290 -254 -223 -144
Net Cash From Continuing Operating Activities		 -86 -138 -251 -290 -254 -223 -144
Net Income / (Loss) Continuing Operations		 -131 -285 -356 -269 -283 -267 -244
Consolidated Net Income / (Loss)		 -131 -285 -356 -269 -283 -267 -244
Depreciation Expense		 1.83 5.92 11 16 18 16 13
Non-Cash Adjustments To Reconcile Net Income		 21 10 26 41 43 38 68
Changes in Operating Assets and Liabilities, net		 23 131 68 -77 -30 -10 19
Net Cash From Investing Activities		 -88 -253 -246 211 172 17 -40
Net Cash From Continuing Investing Activities		 -88 -253 -246 211 172 17 -40
Purchase of Property, Plant & Equipment		 -26 -24 -30 -21 -20 -33 -0.94
Purchase of Investments		 -142 -387 -491 -79 -158 -226 -87
Sale of Property, Plant & Equipment		 - - - - 0.00 0.00 1.43
Sale and/or Maturity of Investments		 83 159 280 310 350 277 47
Net Cash From Financing Activities		 224 436 632 4.91 32 200 129
Net Cash From Continuing Financing Activities		 224 436 632 4.91 32 200 129
Issuance of Common Equity		 0.00 0.00 632 4.91 32 192 129
Other Financing Activities, net		 0.00 0.15 0.00 0.00 0.00 7.74 -0.35

Quarterly Cash Flow Statements for Sana Biotechnology

This table details how cash moves in and out of Sana Biotechnology's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -12 -35 44 -42 -7.96 0.57 -31 -25 32 -31 12
Net Cash From Operating Activities		 -64 -52 -66 -59 -52 -47 -49 -33 -29 -33 -37
Net Cash From Continuing Operating Activities		 -64 -52 -66 -59 -52 -47 -49 -33 -29 -33 -37
Net Income / (Loss) Continuing Operations		 0.98 -88 -107 -50 -60 -49 -49 -94 -42 -59 -47
Consolidated Net Income / (Loss)		 0.98 -88 -107 -50 -60 -49 -49 -94 -42 -59 -47
Depreciation Expense		 4.50 11 3.75 3.90 4.06 5.69 3.65 2.86 3.19 3.05 2.39
Non-Cash Adjustments To Reconcile Net Income		 8.41 7.82 13 13 9.89 5.39 5.98 51 5.71 5.63 5.52
Changes in Operating Assets and Liabilities, net		 -77 17 25 -26 -5.84 -9.18 -8.90 6.90 3.82 18 1.93
Net Cash From Investing Activities		 51 15 -77 5.82 42 47 17 7.68 -48 -16 49
Net Cash From Continuing Investing Activities		 51 15 -77 5.82 42 47 17 7.68 -48 -16 49
Purchase of Property, Plant & Equipment		 -2.23 -14 -16 -13 -4.09 -0.44 -0.14 0.11 -0.04 -0.87 -0.29
Purchase of Investments		 -60 -26 -114 -63 -36 -13 -1.68 - -50 -36 -5.59
Sale of Property, Plant & Equipment		 - - 0.00 - - - 0.25 0.38 0.14 0.66 0.25
Sale and/or Maturity of Investments		 114 55 53 81 82 61 18 7.19 1.41 20 55
Net Cash From Financing Activities		 0.19 1.72 186 11 2.08 0.64 0.98 0.56 110 18 -0.13
Net Cash From Continuing Financing Activities		 0.19 1.72 186 11 2.08 0.64 1.07 0.59 109 18 -0.04
Repurchase of Common Equity		 - - - - - - -0.06 - - - -0.10
Issuance of Common Equity		 0.19 1.72 186 3.00 1.91 0.70 1.13 0.59 110 18 0.06

Annual Balance Sheets for Sana Biotechnology

This table presents Sana Biotechnology's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 730 1,129 823 565 501 417
Total Current Assets		 384 558 444 214 161 149
Cash & Equivalents		 125 253 177 134 128 72
Restricted Cash		 - 0.00 6.10 3.83 3.83 4.20
Short-Term Investments		 253 298 247 72 25 67
Prepaid Expenses		 6.20 7.11 14 4.49 4.48 6.10
Plant, Property, & Equipment, net		 47 65 67 71 77 27
Total Noncurrent Assets		 299 506 311 281 263 241
Goodwill		 141 141 141 141 141 141
Intangible Assets		 59 59 59 59 59 59
Other Noncurrent Operating Assets		 66 101 101 81 63 41
Total Liabilities & Shareholders' Equity		 730 1,129 823 565 501 417
Total Liabilities		 299 401 323 278 251 256
Total Current Liabilities		 31 99 112 64 45 79
Short-Term Debt		 - 51 55 0.00 0.00 40
Accounts Payable		 2.25 2.22 2.86 4.11 5.21 1.67
Accrued Expenses		 9.47 10 15 23 13 8.68
Current Employee Benefit Liabilities		 16 21 26 24 14 13
Other Current Liabilities		 3.71 14 12 13 13 15
Total Noncurrent Liabilities		 267 302 212 213 205 177
Capital Lease Obligations		 - 102 96 91 82 64
Other Noncurrent Operating Liabilities		 267 200 116 122 123 113
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -421 729 499 288 251 161
Total Preferred & Common Equity		 -421 729 499 288 251 161
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -421 729 499 288 251 161
Common Stock		 8.22 1,515 1,558 1,626 1,855 2,010
Retained Earnings		 -429 -785 -1,055 -1,338 -1,605 -1,849
Accumulated Other Comprehensive Income / (Loss)		 0.03 -1.37 -4.33 -0.06 0.01 0.03

Quarterly Balance Sheets for Sana Biotechnology

This table presents Sana Biotechnology's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 898 747 707 631 681 619 559 445 362 435 374
Total Current Assets		 500 370 339 280 321 263 210 113 83 162 112
Cash & Equivalents		 163 160 174 168 177 135 127 96 71 103 84
Restricted Cash		 6.10 6.10 6.10 3.83 3.83 3.83 3.83 4.20 4.20 4.20 4.20
Short-Term Investments		 322 189 152 100 134 117 72 8.57 1.40 50 17
Prepaid Expenses		 8.40 15 6.61 7.12 6.35 7.98 7.31 3.84 5.63 4.51 6.36
Plant, Property, & Equipment, net		 67 64 63 68 82 86 83 74 33 30 26
Total Noncurrent Assets		 331 313 306 284 278 269 266 259 246 244 236
Goodwill		 141 141 141 141 141 141 141 141 141 141 141
Intangible Assets		 59 59 59 59 59 59 59 59 59 59 59
Other Noncurrent Operating Assets		 100 103 106 84 79 69 67 59 46 44 36
Total Liabilities & Shareholders' Equity		 898 747 707 631 681 619 559 445 362 435 374
Total Liabilities		 332 319 352 266 306 279 267 236 239 240 254
Total Current Liabilities		 115 103 112 67 53 51 47 33 33 36 86
Short-Term Debt		 59 57 58 0.00 0.00 0.00 0.00 0.00 0.00 0.00 54
Accounts Payable		 3.99 2.33 3.09 9.93 6.10 3.82 2.99 0.99 2.27 1.86 2.12
Accrued Expenses		 15 13 18 19 20 21 15 9.81 7.93 7.99 8.12
Current Employee Benefit Liabilities		 25 17 20 24 14 16 18 9.35 9.41 11 7.58
Other Current Liabilities		 12 13 13 13 13 10.00 11 13 14 14 15
Total Noncurrent Liabilities		 217 216 240 199 253 228 220 203 206 205 168
Capital Lease Obligations		 100 102 100 83 93 89 85 78 72 68 60
Other Noncurrent Operating Liabilities		 117 114 140 116 160 140 134 125 134 137 108
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 566 428 355 366 375 340 292 209 123 195 119
Total Preferred & Common Equity		 566 428 355 366 375 340 292 209 123 195 119
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 566 428 355 366 375 340 292 209 123 195 119
Common Stock		 1,547 1,567 1,607 1,616 1,821 1,836 1,848 1,863 1,871 1,985 2,015
Retained Earnings		 -974 -1,137 -1,251 -1,250 -1,446 -1,496 -1,556 -1,654 -1,748 -1,790 -1,896
Accumulated Other Comprehensive Income / (Loss)		 -6.41 -2.14 -0.87 -0.20 -0.02 -0.02 0.05 0.00 0.00 0.02 -0.00

Annual Metrics And Ratios for Sana Biotechnology

This table displays calculated financial ratios and metrics derived from Sana Biotechnology's official financial filings.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 - - - - - - 266,366,120.00
DEI Adjusted Shares Outstanding		 - - - - - - 266,366,120.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - -0.92
Growth Metrics		 - - - - - - -
Profitability Metrics		 - - - - - - -
Net Operating Profit after Tax (NOPAT)		 -99 -200 -250 -191 -205 -191 -175
Return On Investment Capital (ROIC_SIMPLE)		 - - - -29.33% -54.23% -57.47% -66.12%
Earnings before Interest and Taxes (EBIT)		 -141 -286 -357 -273 -293 -277 -250
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -139 -280 -346 -258 -269 -260 -238
Valuation Ratios		 - - - - - - -
Leverage & Solvency		 - - - - - - -
Liquidity Ratios		 - - - - - - -
Cash Flow Metrics		 - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -220 -356 -275 -164 -197 -122
Efficiency Ratios		 - - - - - - -
Capital & Investment Metrics		 - - - - - - -
Invested Capital		 0.00 20 126 210 169 176 122
Increase / (Decrease) in Invested Capital		 0.00 20 106 84 -41 6.46 -53
Book Value per Share		 $0.00 ($32.36) $3.86 $2.62 $1.46 $1.12 $0.60
Tangible Book Value per Share		 $0.00 ($47.72) $2.80 $1.57 $0.44 $0.23 ($0.15)
Total Capital		 0.00 432 882 651 378 332 265
Total Debt		 0.00 0.00 153 151 91 82 104
Total Long-Term Debt		 0.00 0.00 102 96 91 82 64
Net Debt		 0.00 -412 -603 -289 -118 -75 -38
Capital Expenditures (CapEx)		 26 24 30 21 20 33 -0.49
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -25 -41 -42 -60 -41 -32
Debt-free Net Working Capital (DFNWC)		 0.00 353 510 388 149 115 110
Net Working Capital (NWC)		 0.00 353 459 333 149 115 70
Net Nonoperating Expense (NNE)		 32 85 106 79 78 76 69
Net Nonoperating Obligations (NNO)		 0.00 -412 -603 -289 -118 -75 -38
Total Depreciation and Amortization (D&A)		 1.83 5.92 11 16 25 17 13
Earnings Adjustments		 - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 ($2.14) ($1.43) ($1.46) ($1.16) ($0.96)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 189.54M 188.34M 194.54M 230.89M 253.23M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 ($2.14) ($1.43) ($1.46) ($1.16) ($0.96)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 189.54M 188.34M 194.54M 230.89M 253.23M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 ($2.14) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 166.43M 191.36M 220.45M 225.02M 266.87M
Normalized Net Operating Profit after Tax (NOPAT)		 -99 -200 -250 -191 -205 -191 -144
Debt Service Ratios		 - - - - - - -
Payout Ratios		 - - - - - - -

Quarterly Metrics And Ratios for Sana Biotechnology

This table displays calculated financial ratios and metrics derived from Sana Biotechnology's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - - - - 266,366,120.00 266,866,897.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - 266,366,120.00 266,866,897.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - -0.22 -0.18
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
EBITDA Growth		 103.19% -1.92% -33.95% 55.69% -2,329.91% 43.25% 56.32% -84.52% 31.62% - 2.06%
EBIT Growth		 97.82% -10.44% -31.48% 54.03% -3,228.17% 44.02% 54.50% -76.43% 30.96% - 4.41%
NOPAT Growth		 96.38% -10.80% -31.73% 57.54% -1,882.24% 43.87% 54.27% -92.37% 29.54% - 3.98%
Net Income Growth		 101.16% -9.54% -30.87% 55.88% -6,189.84% 44.31% 54.05% -86.51% 29.66% - 4.41%
EPS Growth		 100.00% -4.76% -13.95% 64.41% 0.00% 52.27% 57.14% -85.71% 36.00% - 19.05%
Operating Cash Flow Growth		 1.92% 31.69% 17.21% 0.44% 18.46% 9.23% 25.86% 43.46% 43.21% - 23.18%
Free Cash Flow Firm Growth		 109.46% 84.19% 95.03% 47.50% -271.47% -87.73% -560.51% 56.68% 193.27% - 127.23%
Invested Capital Growth		 -12.99% -19.50% -30.84% -4.92% -0.96% 3.81% 16.55% -32.06% -39.51% - -28.34%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
EBITDA Q/Q Growth		 102.34% -3,127.66% -34.54% 53.54% -17.84% 22.95% -3.78% -95.84% 56.33% - 21.28%
EBIT Q/Q Growth		 98.39% -4,725.29% -21.95% 51.59% -16.84% 18.84% 0.68% -87.33% 54.27% - 21.30%
NOPAT Q/Q Growth		 97.32% -2,808.45% -22.19% 55.41% -25.09% 17.64% 0.46% -87.59% 54.18% - 20.56%
Net Income Q/Q Growth		 100.86% -9,054.98% -21.97% 53.21% -19.15% 18.11% -0.65% -89.92% 55.06% - 19.75%
EPS Q/Q Growth		 100.00% 0.00% -11.36% 57.14% -19.05% 16.00% 0.00% -85.71% 58.97% - 15.00%
Operating Cash Flow Q/Q Growth		 -8.08% 18.24% -26.32% 10.80% 11.48% 8.99% -3.17% 31.97% 11.09% - -14.52%
Free Cash Flow Firm Q/Q Growth		 149.64% -192.51% 58.93% -178.37% -62.12% -1.28% -44.51% 81.74% 449.07% - 56.60%
Invested Capital Q/Q Growth		 -2.67% -4.21% -9.58% 12.79% 1.38% 0.41% 1.51% -34.26% -9.73% - 4.48%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Tax Burden Percent		 100.00% 99.95% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% - 100.00%
Interest Burden Percent		 -52.40% 97.29% 97.25% 94.01% 95.87% 96.74% 98.03% 99.39% 97.68% - 98.03%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Equity (ROE)		 -59.15% -72.00% -76.82% -70.51% -92.90% -99.17% -71.44% -109.12% -96.11% - -147.41%
Cash Return on Invested Capital (CROIC)		 -90.84% -86.46% -83.06% -94.85% -123.33% -114.34% -105.04% -86.44% -70.30% - -80.44%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Common Equity (ROCE)		 -59.15% -72.00% -76.82% -70.51% -92.90% -99.17% -71.44% -109.12% -96.11% - -147.41%
Return on Equity Simple (ROE_SIMPLE)		 -75.33% 0.00% -82.26% -72.10% -104.56% 0.00% -99.81% 0.00% 0.00% - 0.00%
Net Operating Profit after Tax (NOPAT)		 -2.18 -63 -78 -35 -43 -36 -35 -66 -30 -43 -34
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Net Nonoperating Expense Percent (NNEP)		 1.15% -12.13% -13.98% -9.25% -10.90% -13.97% -11.04% -31.74% -11.31% - -120.31%
Return On Investment Capital (ROIC_SIMPLE)		 - -16.76% - - - -10.72% -12.33% -34.23% -11.57% -16.17% -14.59%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Earnings before Interest and Taxes (EBIT)		 -1.88 -91 -111 -53 -63 -51 -50 -94 -43 -61 -48
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 2.62 -79 -107 -50 -58 -45 -47 -92 -40 -58 -46
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.08 2.80 5.88 3.56 3.16 1.45 1.81 5.02 4.32 - 6.45
Price to Tangible Book Value (P/TBV)		 4.59 9.17 12.57 8.65 9.99 7.18 40.84 0.00 0.00 - 0.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Enterprise Value to Invested Capital (EV/IC)		 3.24 4.05 12.94 6.04 4.61 1.65 1.95 5.20 7.13 - 6.08
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.23 0.32 0.25 0.26 0.29 0.33 0.37 0.58 0.35 - 0.96
Long-Term Debt to Equity		 0.23 0.32 0.25 0.26 0.29 0.33 0.37 0.58 0.35 - 0.51
Financial Leverage		 -0.59 -0.52 -0.53 -0.49 -0.47 -0.36 -0.43 -0.37 -0.42 - -0.07
Leverage Ratio		 1.64 1.76 1.78 1.91 1.81 1.98 1.93 2.12 2.04 - 2.49
Compound Leverage Factor		 -0.86 1.72 1.73 1.79 1.73 1.92 1.89 2.11 1.99 - 2.45
Debt to Total Capital		 18.56% 24.02% 19.85% 20.68% 22.62% 24.58% 27.25% 36.90% 25.79% - 48.88%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 22.96%
Long-Term Debt to Total Capital		 18.56% 24.02% 19.85% 20.68% 22.62% 24.58% 27.25% 36.90% 25.79% - 25.92%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Common Equity to Total Capital		 81.44% 75.98% 80.15% 79.32% 77.38% 75.42% 72.75% 63.10% 74.21% - 51.12%
Debt to EBITDA		 -0.31 -0.34 -0.31 -0.39 -0.30 -0.31 -0.40 -0.30 -0.30 - -0.48
Net Debt to EBITDA		 0.71 0.44 0.75 0.73 0.41 0.29 0.16 0.02 0.40 - -0.04
Long-Term Debt to EBITDA		 -0.31 -0.34 -0.31 -0.39 -0.30 -0.31 -0.40 -0.30 -0.30 - -0.26
Debt to NOPAT		 -0.42 -0.44 -0.42 -0.50 -0.39 -0.43 -0.53 -0.40 -0.40 - -0.66
Net Debt to NOPAT		 0.95 0.58 0.99 0.94 0.54 0.39 0.21 0.03 0.53 - -0.05
Long-Term Debt to NOPAT		 -0.42 -0.44 -0.42 -0.50 -0.39 -0.43 -0.53 -0.40 -0.40 - -0.35
Altman Z-Score		 -0.65 -1.79 1.29 -0.66 -1.83 -3.67 -4.40 -5.92 -3.63 - -5.64
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 4.19 3.31 6.07 5.20 4.47 3.54 3.40 2.47 4.55 - 1.29
Quick Ratio		 4.03 3.18 5.88 4.96 4.23 3.36 3.16 2.17 4.31 - 1.17
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 24 -22 -9.20 -26 -42 -42 -61 -11 39 11 17
Operating Cash Flow to CapEx		 -2,845.95% -369.92% -414.21% -448.38% -1,266.04% -10,816.74% 0.00% 0.00% 0.00% - -93,447.50%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 177 169 153 173 175 176 178 117 106 122 128
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Increase / (Decrease) in Invested Capital		 -26 -41 -68 -8.94 -1.70 6.46 25 -55 -69 -53 -51
Enterprise Value (EV)		 573 686 1,982 1,042 808 289 347 611 755 - 777
Market Capitalization		 762 804 2,204 1,209 925 364 378 616 844 - 769
Book Value per Share		 $1.86 $1.46 $1.70 $1.53 $1.31 $1.12 $0.93 $0.54 $0.82 $0.60 $0.45
Tangible Book Value per Share		 $0.84 $0.44 $0.80 $0.63 $0.42 $0.23 $0.04 ($0.34) ($0.02) ($0.15) ($0.30)
Total Capital		 449 378 468 428 378 332 287 194 263 265 233
Total Debt		 83 91 93 89 85 82 78 72 68 104 114
Total Long-Term Debt		 83 91 93 89 85 82 78 72 68 64 60
Net Debt		 -189 -118 -222 -167 -117 -75 -31 -5.21 -89 -38 8.68
Capital Expenditures (CapEx)		 2.23 14 16 13 4.09 0.44 -0.12 -0.49 -0.10 0.21 0.04
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -60 -60 -47 -43 -40 -41 -29 -28 -31 -32 -26
Debt-free Net Working Capital (DFNWC)		 213 149 268 213 163 115 80 49 126 110 79
Net Working Capital (NWC)		 213 149 268 213 163 115 80 49 126 70 25
Net Nonoperating Expense (NNE)		 -3.17 25 30 16 17 13 14 27 12 16 13
Net Nonoperating Obligations (NNO)		 -189 -118 -222 -167 -117 -75 -31 -5.21 -89 -38 8.68
Total Depreciation and Amortization (D&A)		 4.50 11 3.75 3.90 4.06 5.69 3.65 2.86 3.19 3.05 2.39
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($0.44) ($0.49) ($0.21) ($0.25) ($0.21) ($0.21) ($0.39) ($0.16) ($0.20) ($0.17)
Adjusted Weighted Average Basic Shares Outstanding		 196.98M 194.54M 217.29M 234.44M 235.41M 230.89M 237.58M 238.41M 260.49M 253.23M 276.86M
Adjusted Diluted Earnings per Share		 $0.00 ($0.44) ($0.49) ($0.21) ($0.25) ($0.21) ($0.21) ($0.39) ($0.16) ($0.20) ($0.17)
Adjusted Weighted Average Diluted Shares Outstanding		 200.47M 194.54M 217.29M 234.44M 235.41M 230.89M 237.58M 238.41M 260.49M 253.23M 276.86M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 197.13M 220.45M 221.50M 222.47M 223.27M 225.02M 225.56M 237.81M 266.37M 266.87M 278.29M
Normalized Net Operating Profit after Tax (NOPAT)		 -1.53 -63 -78 -35 -43 -36 -35 -35 -30 -43 -34
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%

Financials Breakdown Chart

Key Financial Trends

Sana Biotechnology (NASDAQ:SANA) continues to operate as a pre-revenue, early-stage biotech company. Over the last four years, the company has funded its operations primarily through equity raises rather than operating earnings. Below are the key trends drawn from the quarterly statements provided, with a focus on what might matter to retail investors.

  • Significant equity financing has boosted Sana’s liquidity: about $186.4 million raised via common equity in Q4 2024, about $109.6 million in Q3 2025, and about $17.7 million in Q4 2025 (plus smaller raises in earlier periods). These financing events provide runway for ongoing R&D and operations.
  • Ongoing positive financing cash flows across several quarters indicate access to capital markets: notably +$109.5 million from financing activities in Q3 2025, and additional positives in Q4 2024 (+$186.4M) and Q4 2025 (+$17.7M).
  • Low near-term leverage in several quarters: in multiple balance sheets, short-term debt is reported as 0, suggesting the company has not relied on short-term borrowings for liquidity in those periods.
  • Balance sheet reflects investment in the pipeline (intangible assets and goodwill): as of the latest quarterly data, Goodwill is around $140.6 million and Intangible Assets around $59.2 million, indicating substantial prior capitalization of product/technology assets.
  • No current revenue yet in many periods: Total Revenue is reported as 0 in several quarters (e.g., Q4 2025 and prior periods), underscoring Sana’s pre-revenue stage and ongoing focus on R&D rather than sales.
  • R&D and SG&A remain substantial: R&D expense around $49.0 million (Q4 2025) and SG&A around $12.2 million in that same quarter, consistent with heavy investment in the pipeline and core operations.
  • Asset base growth appears to be driven by capitalization and equity funding rather than consistent earnings: total assets span the several hundred million range as equity-funded gains accrue alongside ongoing R&D investment.
  • Persistent net losses: Sana posted notable losses across recent quarters, including net income (loss) of about -$58.8 million in Q4 2025, -$93.8 million in Q2 2025, -$42.2 million in Q3 2025, and -$49.4 million in Q1 2025.
  • Operating cash flow remains negative in recent quarters: net cash from continuing operating activities was approximately -$32.6 million (Q4 2025), -$29.4 million (Q3 2025), -$33.1 million (Q2 2025), and -$48.7 million (Q1 2025), indicating ongoing cash burn despite equity raises.
  • Reliance on equity dilution risk: continued equity financings to fund operations create dilution risk for existing shareholders, especially if funding needs persist before meaningful product milestones or revenue are achieved.
05/19/26 08:04 AM ETAI Generated. May Contain Errors.

Sana Biotechnology Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Sana Biotechnology's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Sana Biotechnology's net income appears to be on an upward trend, with a most recent value of -$244.17 million in 2025, rising from -$130.78 million in 2019. The previous period was -$266.76 million in 2024. Find out what analysts predict for Sana Biotechnology in the coming months.

Sana Biotechnology's total operating income in 2025 was -$250.32 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $250.32 million

Over the last 6 years, Sana Biotechnology's total revenue changed from $0.00 in 2019 to $0.00 in 2025, a change of 0.0%.

Sana Biotechnology's total liabilities were at $256.01 million at the end of 2025, a 2.2% increase from 2024, and a 14.3% decrease since 2020.

In the past 5 years, Sana Biotechnology's cash and equivalents has ranged from $71.87 million in 2025 to $253.03 million in 2021, and is currently $71.87 million as of their latest financial filing in 2025.

Over the last 6 years, Sana Biotechnology's book value per share changed from 0.00 in 2019 to 0.60 in 2025, a change of 60.4%.


Related Companies

Financial statements for NASDAQ:SANA last updated on 5/12/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Why this tiny stock may move before the SpaceX IPO drops
The projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...
Behind the Markets | Sponsoredtc pixel
Satellite Images Spot Potential $10 Trillion Discovery
'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...
Altimetry | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
Is the SpaceX IPO “Rigged?”
The SpaceX IPO filing is official, with 21 banks - including JPMorgan, Goldman Sachs, and Morgan Stanley - pre...
The Oxford Club | Sponsoredtc pixel